SHIFT

Systolic Heart failure treatment with the lf inhibitor ivabradine Trial

Skip to content
  • Home
  • SHIFT
  • IVABRADINE
  • HEART RATE & HEART FAILURE
  • NEWSROOM
  • RESOURCES
  • CONTACT US
Home > SHIFT > SHIFT resources > SHIFT slide sets

NAVIGATION

  • SHIFT study
    • Overview of SHIFT
    • Objective
    • Design
    • End points
    • Primary end point
    • Secondary end points
    • Tolerability
  • SHIFT analyses
    • Recurrent hospitalization
    • Early rehospitalization
    • Elevated heart rate (HR ≥ 75 bpm)
    • Quality of life
    • Echocardiography
    • Concomitant therapy
    • Age
    • Comorbidities
    • Hemodynamic profile
  • SHIFT resources
    • SHIFT investigators
    • SHIFT slide sets
    • SHIFT publications
    • SHIFT prognostic model

SHIFT slide sets

 

Objective, Design & Baseline Main results Elevated heart rate (HR≥75 bpm) Recurrent
hospitalization		 Low Blood Pressure
Quality of life Concomitant therapy-β-blockers Age COPD LBBB
Echo-cardiography Concomitant
therapy-MRAs		 Severe heart failure Hemodynamic
profile		 Renal dysfunction
This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information. This site is published and updated by the SHIFT study investigators-©2021 SHIFT. All rights reserved. Report a side-effect with a drug.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more